Abstract:Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the production of primary prostanoids by blocking the access of arachidonic acid to the active site of the cyclooxygenases (COXs). Because the prostanoids produced by COX-1 appear to play a physiological role (protection of the gastric mucosa, platelet aggregation, vascular homeostasis, maintenance of renal sodium-water balance) while those produced by COX-2 seem mainly to intervene in the inflammatory response and in certain processes associated with cell proliferation, the hypothesis has been put forward that the NSAIDs that are selective COX-2 inhibitors should theoretically be capable of maintaining NSAID therapeutic properties but also have fewer adverse side effects due to the maintenance of prostaglandin production at normal physiological levels. Current knowledge and key points: The hypothesis of COX isoenzyme selectivity has led to a proposed classification for COX inhibitors: 1) COX-1 selective inhibitors (low-dosage aspirin); 2) COX non-selective inhibitors (the majority of classified NSAIDs, which when administered over the long term, e.g., in cases of rheumatoid arthritis, cause duodenal ulcers in 20% of cases and gastric hemorrhage in 1-4% of cases/year); 3) COX-2 preferential inhibitors (meloxicam and nimesulide, which have fewer gastric side effects than standard NSAIDs, but which are not risk-free at high doses); 4) COX-2 selective inhibitors (celecoxib and rofecoxib). Preliminary clinical studies have shown that COX-2 selective inhibitors are as efficient as standard NSAIDs and have fewer adverse digestive side effects, thereby confirming the interest of this proposed classification. In the UK, the aforementioned studies have led to the commercialization of rofecoxib for the treatment of pain and osteoarthritis, while celecoxib has been introduced in medical practice in the USA and other countries for the treatment of rheumatoid arthritis and osteoarthritis. Future prospects and projects: Various epidemiological and laboratory studies have indicated that NSAIDs may be able to reduce the risk of cancer (colorectal cancer in particular) and Alzheimer's disease due to their inhibitory activity on COXs, especially COX-2. The therapeutic contribution of COX-2 specific inhibitors has to be more fully evaluated, particularly as these agents could delay the healing of duodenal ulcers and interfere with several COX-2-induced physiological functions. It is therefore suggested that until further information becomes available, this new class of NSAIDs should be used with caution in certain patient populations.

For Discussion NSAIDs: gastroprotection or selective COX-2 inhibitor?

Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents

Primer: Managing NSAID-induced Ulcer Complications—balancing Gastrointestinal and Cardiovascular Risks

Nonsteroidal Anti‐Inflammatory Drug‐Gastropathy and Enteropathy

The David Y. Graham Lecture: Use of Nonsteroidal Antiinflammatory Drugs in a COX-2 Restricted Environment

[Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects]

Evolution of Novel Non-Steroidal Anti-Inflammatory Drugs with Reduced Gastrointestinal Adverse Effects

Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration

Safety and rational choice of non-steroidal anti-inflammatory drugs

Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale

[Selective COX-2 Inhibitor Versus Nonselective COX-1 and COX-2 Inhibitor in the Prevention of Heterotopic Ossification after Total Hip Arthroplasty: a Meta-Analysis of Randomised Trials].

Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment

Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Gastroprotective NSAIDs on the Gastrointestinal Tract: A Narrative Review

Concomitant suppression of COX-1 and COX-2 is insufficient to induce enteropathy associated with chronic NSAID use

NSAIDs, Risks, and Gastroprotective Strategies: Current Status and Future

Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.

Nonsteroid Anti-Inflammatory Drug-Induced Gastroduodenal Injury

NSAID-induced gastrointestinal and cardiovascular injury.

Cyclooxygenase-2 Inhibitors in Patients with High Gastrointestinal Risk: Are We There Yet?

Systematic Review with Network Meta-Analysis: Comparative Effectiveness and Safety of Strategies for Preventing NSAID-associated Gastrointestinal Toxicity

Proton Pump Inhibitors in Gastroprotection: Prevention and Healing of Nonsteroidal Anti-Inflammatory Drug-, Aspirin-, and Cyclooxygenase-2 Inhibitor-Induced Gastroduodenal Lesions